Combining CRA with PD-L1 antibodies enhances CD8+ T cell responses, reduces immunosuppressive cells, and overcomes resistance, making it a potential treatment for advanced or unresectable HCC[73]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.